Dolutegravir and lamivudine

  • Part D specialty tier in 80% of formularies (2026Q3)
  • Dovato

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Dolutegravir and lamivudine: storage and handling

Freezing
Not addressed
Room temperature
No allowance stated
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

The label does not state a room-temperature allowance for this product.

Entered: 1 day at up to 77°F (25°C).

Contact the manufacturer at 1-877-844-8872 (the number printed on the label) about this product.

Where the label prints this number
DVT:11PIL For more information go to www.DOVATO.com or call 1-877-844-8872.
All storage statements on the label (3)
  • Store below 30°C (86°F).
  • How should I store DOVATO? .
  • Store DOVATO below 86°F (30°C). .

FDA label version 19, effective October 29, 2025. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

100%of plans list it
0%of those: prior authorization
0%step therapy
52%quantity limit
96%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.